Monopar Therapeutics (MNPR) Share-based Compensation (2017 - 2025)

Quarterly results put Share-based Compensation at -$3.7 million for Q4 2025, down 1440.13% from a year ago — trailing twelve months through Dec 2025 was -$1.2 million (down 253.47% YoY), and the annual figure for FY2024 was $1.1 million, down 39.89%.

Monopar Therapeutics has reported Share-based Compensation over the past 9 years, most recently at -$3.7 million for Q4 2025.

  • Share-based Compensation reached -$3.7 million in Q4 2025 per MNPR's latest filing, down from $617413.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.4 million in Q1 2025 and bottomed at -$3.7 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $357593.0 (2021), compared with a mean of $178382.8.
  • Peak annual rise in Share-based Compensation hit 4469.37% in 2025, while the deepest fall reached 1440.13% in 2025.
  • Over 5 years, Share-based Compensation stood at $392065.0 in 2021, then grew by 0.34% to $393417.0 in 2022, then grew by 20.54% to $474206.0 in 2023, then plummeted by 41.25% to $278612.0 in 2024, then tumbled by 1440.13% to -$3.7 million in 2025.
  • Business Quant data shows Share-based Compensation for MNPR at -$3.7 million in Q4 2025, $617413.0 in Q3 2025, and $567957.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 892,057.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 305,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 166.40 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 257.40 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 70.15 Mn
10 Monopar Therapeutics 466.82 Mn 466.82 Mn - -3.73 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -3.73 Mn
Dec 31, 2025 -3.73 Mn
Sep 30, 2025 617,413.00
Sep 30, 2025 617,413.00
Jun 30, 2025 567,957.00
Jun 30, 2025 567,957.00
Mar 31, 2025 1.36 Mn
Mar 31, 2025 1.36 Mn
Dec 31, 2024 278,612.00
Dec 31, 2024 278,612.00
Sep 30, 2024 13,512.00
Sep 30, 2024 13,512.00
Jun 30, 2024 156,822.00
Jun 30, 2024 156,822.00
Mar 31, 2024 328,661.00
Mar 31, 2024 328,661.00
Dec 31, 2023 474,206.00
Dec 31, 2023 474,206.00
Sep 30, 2023 217,468.00
Sep 30, 2023 217,468.00
Jun 30, 2023 216,999.00
Jun 30, 2023 216,999.00
Mar 31, 2023 476,209.00
Mar 31, 2023 476,209.00
Dec 31, 2022 393,417.00
Dec 31, 2022 393,417.00
Sep 30, 2022 204,360.00
Sep 30, 2022 204,360.00
Jun 30, 2022 204,692.00
Jun 30, 2022 204,692.00
Mar 31, 2022 499,812.00
Mar 31, 2022 499,812.00
Sep 30, 2021 392,065.00
Sep 30, 2021 392,065.00
Jun 30, 2021 357,593.00
Jun 30, 2021 357,593.00
Mar 31, 2021 368,232.00
Mar 31, 2021 368,232.00
Dec 31, 2020 331,322.00
Dec 31, 2020 331,322.00
Sep 30, 2020 283,713.00
Sep 30, 2020 283,713.00
Jun 30, 2020 367,358.00
Jun 30, 2020 367,358.00
Mar 31, 2020 338,497.00
Mar 31, 2020 338,497.00
Dec 31, 2019 276,805.00
Dec 31, 2019 276,805.00
Sep 30, 2019 242,956.00
Sep 30, 2019 242,956.00
Jun 30, 2019 257,633.00
Jun 30, 2019 257,633.00
Mar 31, 2019 233,776.00
Mar 31, 2019 233,776.00
Dec 31, 2018 232,992.00
Dec 31, 2018 232,992.00
Sep 30, 2018 93,244.00
Sep 30, 2018 93,244.00
Jun 30, 2018 88,570.00
Jun 30, 2018 88,570.00
Mar 31, 2018 114,526.00
Mar 31, 2018 114,526.00
Dec 31, 2017 63,189.00
Dec 31, 2017 63,189.00
Sep 30, 2017 3,612.00
Sep 30, 2017 3,612.00